Zimbus Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbations) in the last year. Zimbus Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.
Therapeutic Indication
### Therapeutic indication Maintenance treatment of asthma in adults whose disease is not adequately controlled.
Therapeutic Area (MeSH)
N/AATC Code
R03AL
ATC Item
抗胆碱能与抗胆碱能结合/三重组合与糖皮质激素
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| glycopyrronium bromide | N/A | 格隆溴铵 |
| mometasone furoate | N/A | 莫米松 |
| Glycopyrronium bromide | N/A | 格隆溴铵 |
| Indacaterol (acetate) | N/A | Indacaterol Maleate/Glycopyrronium Bromide/Mometasone furoate |
| Mometasone furoate | N/A | 莫米松 |
EMA Name
Zimbus Breezhaler
Medicine Name
Zimbus Breezhaler
Aliases
N/ANo risk management plan link.
